On June 3, 2021 Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported that the first patient has been dosed in the Company’s Phase 1b study of VIP152 in MYC-driven relapsed or refractory (R/R) aggressive lymphomas and advanced solid tumors (Press release, Vincerx Pharma, JUN 3, 2021, View Source [SID1234583496]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Vincerx has achieved a significant milestone with the first dosing of a patient in a Vincerx-sponsored clinical trial," said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. "This trial builds upon the encouraging signals of monotherapy activity observed in the dose-escalation study and exploratory cohort in double-hit lymphoma, which includes clinically significant monotherapy activity in patients with advanced malignancies and a favorable safety profile. We believe our comprehensive clinical strategy, which explores the potential of potent and specific PTEFb/CDK9 inhibition with VIP152 in MYC-driven indications, positions us to pursue multiple registration paths. We look forward to the continued expansion of our strategic clinical programs with the initiation of our Phase 1 dose escalation study in CLL relapsed/refractory to venetoclax and BTK inhibitors in the second half of this year."
The ongoing Phase 1b expansion, first-in-human (FIH) study is in patients with advanced cancer and consists of two expansion arms. Arm 1 will enroll up to 30 patients with relapsed/refractory aggressive lymphoma, including DLBCL, transformed follicular lymphoma, and blastoid mantle cell lymphoma. Arm 2 will enroll up to 40 patients with advanced solid tumors, including patients with ovarian cancer, triple negative breast cancer, castration-resistant neuroendocrine prostate cancer, and any other solid tumor with MYC aberration. All patients must have confirmed MYC overexpression or translocation.
Previously, early signs of clinical activity at higher dose levels were observed with durable disease control in individual patients with pancreatic cancer and salivary gland cancer (~10 and ~17 months of treatment, respectively). Of the 31 subjects dosed, a patient with double-hit lymphoma (DHL) from the 30-mg cohort achieved a complete metabolic response (CMR) followed by the enrollment of an additional 6 DHL patients in an exploratory cohort with a CMR observed in 29% (2 of 7) patients. Due to the COVID pandemic, the patients with CMR withdrew consent after 3.7 and 2.3 years, respectively, of treatment. Both patients were in CMR at study exit.